Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study.
Cas J IsfordinkThijs J W van de LaarSjoerd P H RebersEls WesselsRichard MolenkampMarjolein KnoesterBert C BaakCees van NieuwkoopBart van HoekSylvia M BrakenhoffHans BlokzijlJoop E ArendsMarc van der ValkJanke SchinkelPublished in: Open forum infectious diseases (2021)
The DAA efficacy we observed in most nonepidemic genotypes in the Netherlands seems reassuring. However, the low SVR-12 rate in subtype 3b infections is alarming, especially as it is common in several HCV-endemic countries. Alongside earlier results, our results indicate that a remaining challenge for global HCV elimination is confirming and monitoring DAA efficacy in nonepidemic genotypes.